Gülin Uçmak

Gülin Uçmak

Auto-generated profile, based on publicly available information

Gülin Uçmak

SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, ANKARA DR. ABDURRAHMAN YURTASLAN ONKOLOJİ SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2022 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
SASeda Gülbahar Ateş
Seda Gülbahar Ateş
GUGülin Uçmak
Gülin Uçmak
Multiple myeloma (MM) is a hematologic malignancy associated with uncontrolled clonal proliferation of plasma cells. Extramedullary disease in MM is an aggressive entity with a poor prognosis. Moreover, involvement of the gastrointestinal tract is a rare aggressive biological sign. 18F-FDG PET/CT is an irreplaceable modality in the assessment of extramedullary disease. We present 2 cases with gastric involvement of MM that were shown by 18F-FDG PET/CT and confirmed as plasma cell infiltration pathologically. 18F-FDG PET/CT studies of MM patients should be interpreted carefully for gastrointestinal involvement, and it should be kept in mind that it can mimic other malignancies.

24 December 2020 in Nuclear Medicine Seminars
Verified
Journal Article
Closed access
GUGülin Uçmak
Gülin Uçmak
ISİlknur Ak Sivrikoz
İlknur Ak Sivrikoz
NSNalan Alan Selçuk
Nalan Alan Selçuk
EDemre demirci
emre demirci
UEUmut Elboga
Umut Elboga
LKLevent Kabasakal
Levent Kabasakal

28 June 2021 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
AFAykut Kürşat Fi̇dAn
Aykut Kürşat Fi̇dAn
GUGülin Uçmak
Gülin Uçmak
BDBedriye Büşra Demi̇rEl
Bedriye Büşra Demi̇rEl
HEHulya Efeturk
Hulya Efeturk
IÖİpEk Öztürk
İpEk Öztürk
IIİnCi Ergürhan İlHan
İnCi Ergürhan İlHan
The aim of this study was to investigate the contribution of fluorine-18 (F-18) fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) imaging in staging of pediatric osteosarcoma patients and also to evaluate the ability of metabolic parameters from the primary tumor to predict tumor necrosis rate (TNR). F-18 FDG-PET/CT imaging was performed in staging 37 pediatric osteosarcoma patients. The metabolic parameters SUVmax (maximum standardised uptake value), MTV (metabolic tumour volume) and TLG (total lesion glycolysis) were measured from the primary tumor. TNR level of the primary tumor was histopathologically measured after standard neoadjuvant chemotherapy treatment. The contribution of F-18 FDG-PET/CT to staging of pediatric osteosarcoma patients and the accuracy of metabolic parameters of the primary tumor to predict TNR were analized by regression analysis. MTV and TLG of the primary tumor were found to efficiently predict histopathologic TNR, whereas SUVmax was not (p=0.012, p=0.027, p=0.25, respectively). Also 5 of 12 patients (41.6%) who were initially defined as localised osteosarcoma were upstaged in consequence of staging F-18 FDG-PET/CT findings. F-18 FDG-PET/CT staging in pediatric osteosarcoma patients can effectively distinguish metastatic-localised disease. MTV and TLG values are important parameters which can efficiently be used to predict TNR.

2 August 2024 in Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
Verified
Journal Article
Closed access
SASeda Gülbahar Ateş
Seda Gülbahar Ateş
BDBedriye Büşra Demirel
Bedriye Büşra Demirel
EKEsra Kekilli
Esra Kekilli
EÖErdem Öztürk
Erdem Öztürk
GUGülin Uçmak
Gülin Uçmak

23 February 2024 in Molecular Imaging and Radionuclide Therapy
Verified
Journal Article
Open access
SASeda Gülbahar Ateş
Seda Gülbahar Ateş
BDBedriye Büşra Demirel
Bedriye Büşra Demirel
HBHalil Basar
Halil Basar
GUGülin Uçmak
Gülin Uçmak
Objectives: This retrospective study aimed to evaluate the prognostic importance of F-18-fluorodeoxyglucose (F-18-FDG)-positive pelvic lymph nodes (LNs) and extra -pelvic disease on staging F-18-FDG positron emission tomography/computed tomography (PET/CT) in patients with bladder cancer. Methods: Bladder cancer patients who underwent staging F-18-FDG PET/CT were included in the study. Histopathologic features of tumors, therapy histories, presence of distinguishable tumors on CT and PET images, sizes and maximum standardized uptake value (SUVmax) of primary tumors, total numbers, sizes, and SUVmax of F-18-FDG-positive pelvic and extra -pelvic LNs, and total numbers and SUVmax of distant metastases (M1a/1b) were recorded. Patients were followed up until death or the last medical visit. Factors predicting overall survival were determined using Cox regression analysis. Results: Fifty-five patients [median age: 70 (53-84), 48 (87.3%) male, 7 (12.7%) female] with bladder cancer were included in this study. Twentynine (52.7%) patients had 18F-FDG positive pelvic LNs, while 24 (43.7%) patients had 18F-FDG positive extra -pelvic disease. Patients with F-18-FDG- positive pelvic LNs had a higher rate of extra -pelvic disease (p=0.003). The median follow-up duration was 13.5 months. The median overall survival was 16.3 months [95% confidence interval (CI) 8.9-23.7]. The primary tumor distinguishability on PET (p=0.011) and CT (p=0.009) images, the presence of F-18-FDG-positive pelvic LNs (p<0.001) and F-18-FDG-positive extra -pelvic disease/distant metastases (M1a/M1b) (p<0.001), and the number of distant metastases (p=0.034) were associated with mortality. The F-18-FDG-positive extra -pelvic disease/distant metastases [p=0.029, odds ratio: 4.15 (95% CI 1.16-14.86)] was found to be an independent predictor of mortality in patients with bladder cancer. Conclusion: The presence of 18F-FDG-positive extra -pelvic disease in pretreatment 18F-FDG PET/CT is an important prognostic factor in bladder cancer patients.

24 December 2020 in Nuclear Medicine Seminars
Verified
Journal Article
Closed access
CSCigdem Soydal
Cigdem Soydal
ZBZeynep Burak
Zeynep Burak
GUGülin Uçmak
Gülin Uçmak
MBMurat Fani BOZKURT
Murat Fani BOZKURT
TATamer Atasever
Tamer Atasever
ISİlknur Ak Sivrikoz
İlknur Ak Sivrikoz